

Comment on COMMANDER Thrombotic Events Substudy




Freek W.A. Verheugt



Amsterdam, Netherlands

Onze Lieve Vrouwe Gasthuis (OLVG), Amsterdam

Trials with Warfarin in Heart Failure with Sinus Rhythm




¹ *Am Heart J* 2004;148:157-164

² *Circulation* 2009;119:1616-1624

³ *N Engl J Med* 2012;366:1859-1869

KM Estimates for MI and Ischemic Stroke in COMMANDER


Myocardial Infarction



Subjects at risk

Rivaroxaban	2507	2409	2318	2173	1899	1654	1404	1211	995	836	682	600	517	432	334	243	124	46
Placebo	2515	2418	2323	2168	1875	1612	1378	1189	981	825	682	602	520	440	346	247	134	47


Ischemic Stroke




Subjects at risk

Rivaroxaban	2507	2425	2335	2191	1916	1670	1418	1219	1002	840	687	607	522	440	341	248	127	48
Placebo	2515	2427	2335	2182	1898	1631	1388	1197	983	828	681	602	522	444	344	247	130	44

ROLE OF THROMBIN IN CORONARY THROMBOSIS




Warfarin vs Aspirin after MI (WARIS-2 (n =3,630) & ASPECT-2 (n = 999))




Death, MI or stroke

WARIS-2. *N Engl J Med* 2002;347:969-974



Death, MI or stroke



Death


ASPECT-2. *Lancet* 2002;360:109-113

COMPASS: Primary Endpoint

Primary: CV death, stroke, MI



Population Health
Research Institute
HEALTH THROUGH KNOWLEDGE



No. at Risk	0	1	2	3
Rivaroxaban + Aspirin	9152	7904	3912	658
Rivaroxaban	9117	7824	3802	670
Aspirin	9126	7808	3860	669

N Engl J Med 2017;377:1319-1330

COMPASS: Primary Endpoint

Primary components

Outcome	R + A N=9,152	A N=9,126	Rivaroxaban + Aspirin vs. Aspirin	
	N (%)	N (%)	HR (95% CI)	p
CV death	160 (1.7%)	203 (2.2%)	0.78 (0.64-0.96)	0.02
Stroke	83 (0.9%)	142 (1.6%)	0.58 (0.44-0.76)	<0.0001
MI	178 (1.9%)	205 (2.2%)	0.86 (0.70-1.05)	0.14

Conclusions

- 1.** Although COMMANDER HF did not meet its primary endpoint, oral anticoagulation did prevent ischemic endpoints (ischemic stroke and MI).
- 2.** These results underscore the long-term benefit of oral anticoagulation in chronic CAD, as found in the old post-MI trials with warfarin and now in modern times in the recent COMPASS and COMMANDER trials.